Diabetic-hypertensive Pre-heart Failure
An Issue of Heart Failure Clinics
Seiten
2006
Saunders (Verlag)
978-1-4160-3464-3 (ISBN)
Saunders (Verlag)
978-1-4160-3464-3 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Early recognition and proper treatment of high blood pressure, diabetes and other cardiovascular risk factors can help patients delay or avoid heart failure. This book discusses metabolic-related precursors to heart failure, as well as the use of beta-blockers and other medications that can be used to treat pre-heart failure.
Early recognition and proper treatment of high blood pressure, diabetes and other cardiovascular risk factors can help patients delay or avoid heart failure. However, the number of people living with these early stages of heart failure is steadily increasing. Leading experts discuss metabolic-related precursors to heart failure, as well as the use of beta-blockers and other medications that can be used to treat pre-heart failure in this issue.
Early recognition and proper treatment of high blood pressure, diabetes and other cardiovascular risk factors can help patients delay or avoid heart failure. However, the number of people living with these early stages of heart failure is steadily increasing. Leading experts discuss metabolic-related precursors to heart failure, as well as the use of beta-blockers and other medications that can be used to treat pre-heart failure in this issue.
Erscheint lt. Verlag | 5.2.2007 |
---|---|
Reihe/Serie | The Clinics: Internal Medicine ; v. 2-1 |
Zusatzinfo | Illustrations |
Verlagsort | Philadelphia |
Sprache | englisch |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Diabetologie |
Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie | |
ISBN-10 | 1-4160-3464-1 / 1416034641 |
ISBN-13 | 978-1-4160-3464-3 / 9781416034643 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Buch | Softcover (2022)
Urban & Fischer in Elsevier (Verlag)
CHF 75,60
Vol. 1 & 2
Buch | Hardcover (2022)
McGraw-Hill Companies (Verlag)
CHF 284,90